Trending Stock News

EPS for Top Image Systems Ltd. (TISA) Expected At $-0.04; Last Week Flex Pharma, Inc. (FLKS) Coverage

Among 5 analysts covering Flex Pharma (NASDAQ:FLKS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Flex Pharma had 7 analyst reports since August 21, 2015 according to SRatingsIntel. Zacks upgraded Flex Pharma, Inc. (NASDAQ:FLKS) on Wednesday, September 2 to “Hold” rating. Cantor Fitzgerald maintained Flex Pharma, Inc. (NASDAQ:FLKS) on Tuesday, July 25 with “Hold” rating. Cantor Fitzgerald downgraded the shares of FLKS in report on Friday, October 14 to “Hold” rating. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, August 3 report. The rating was downgraded by Zacks on Friday, August 21 to “Hold”. On Thursday, September 7 the stock rating was initiated by Roth Capital with “Buy”. See Flex Pharma, Inc. (NASDAQ:FLKS) latest ratings:

25/01/2018 Broker: Ladenburg Thalmann Rating: Buy New Target: $12 Initiates Coverage On
07/09/2017 Broker: Roth Capital Rating: Buy New Target: $14.0 Initiate

Analysts expect Top Image Systems Ltd. (NASDAQ:TISA) to report $-0.04 EPS on March, 8.They anticipate $0.17 EPS change or 80.95% from last quarter’s $-0.21 EPS. After having $-0.08 EPS previously, Top Image Systems Ltd.’s analysts see -50.00% EPS growth. The stock increased 4.29% or $0.0438 during the last trading session, reaching $1.0638. About 700 shares traded. Top Image Systems Ltd. (NASDAQ:TISA) has declined 30.56% since February 13, 2017 and is downtrending. It has underperformed by 47.26% the S&P500.

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company has market cap of $73.68 million. The firm operates through two divisions, Consumer Operations and Drug Development. It currently has negative earnings. The Company’s lead drug candidate includes FLX-787, a single molecule, chemically synthesized, and transient receptor potential ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis and amyotrophic lateral sclerosis.

The stock decreased 0.24% or $0.01 during the last trading session, reaching $4.1. About 29,963 shares traded. Flex Pharma, Inc. (NASDAQ:FLKS) has declined 70.24% since February 13, 2017 and is downtrending. It has underperformed by 86.94% the S&P500.

Among 4 analysts covering Top Image Systems (NASDAQ:TISA), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Top Image Systems had 9 analyst reports since August 12, 2015 according to SRatingsIntel. As per Friday, November 17, the company rating was maintained by H.C. Wainwright. The firm earned “Buy” rating on Monday, July 10 by H.C. Wainwright. The company was maintained on Wednesday, August 12 by Benchmark. The firm has “Buy” rating given on Friday, March 11 by H.C. Wainwright. On Thursday, August 17 the stock rating was maintained by H.C. Wainwright with “Buy”. The company was upgraded on Friday, August 14 by Zacks. The rating was downgraded by Benchmark on Wednesday, November 11 to “Hold”. The rating was maintained by Roth Capital with “Buy” on Thursday, August 17. The firm earned “Buy” rating on Tuesday, November 10 by TH Capital.

Leave a Reply

Your email address will not be published. Required fields are marked *